Multistate Antitrust Risk Features in Generic Drug Price-Fixing Case

A coalition of 48 states and territories has recently announced settlements totaling $17.85 million with several generic drug manufacturers over allegations that the companies participated in long-running price-fixing conspiracies and unreasonably restrained trade of numerous generic prescription drugs.

Buchalter wrote about the case against Lannett Company, Inc. and Bausch Health US, LLC, and Bausch Health Americas, Inc. on the firm’s website. The settlements were announced Feb. 2, 2026.

The agreements are part of a broader multi-state antitrust litigation effort that began in 2016 and is now advancing toward a first trial in Connecticut. The coalition’s claims center on alleged competitor coordination across the generic drug industry.

Plaintiffs allege that executives from competing manufacturers communicated regularly at industry events, social gatherings, and private meetings, and used those contacts to coordinate pricing and market behavior.

The states claim that the defendants used coded phrases like “fair share” and “playing nice in the sandbox,” which are evidence of shared unlawful understandings. Investigators built their record from millions of call records and contemporaneous notes from cooperating witnesses.

Three related antitrust complaints have been filed. Cooperation agreements with settling defendants are being used to press claims against remaining corporate defendants and individual executives.

The settlements reflect a litigation campaign with a repeatable playbook. The states have built a scalable evidentiary framework linking competitor communications to real-world pricing moves and market shifts. Settlement terms include compliance obligations extending beyond monetary payments.

Antitrust counsel should treat this litigation as a live benchmark for enterprise risk management in industries with concentrated markets and frequent competitor contact. Companies should audit internal communications, employee participation at trade events, and pricing governance protocols. Counsel advising pharmaceutical and other regulated-industry clients should evaluate antitrust compliance programs against the conduct patterns the states have now publicly mapped.